2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0180R
    Imiquimod (Standard)
    		Inhibitor
    Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
    Imiquimod (Standard)
  • HY-P5407
    HD5
    		Inhibitor
    HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
    HD5
  • HY-B1400R
    Diiodohydroxyquinoline (Standard)
    		Inhibitor
    Diiodohydroxyquinoline (Standard) is the analytical standard of Diiodohydroxyquinoline. This product is intended for research and analytical applications. Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas.
    Diiodohydroxyquinoline (Standard)
  • HY-157848
    SARS-CoV-2-IN-82
    		Inhibitor
    SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2.
    SARS-CoV-2-IN-82
  • HY-N1951R
    Miltirone (Standard)
    		Inhibitor
    Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoV main protease (Mpro).
    Miltirone (Standard)
  • HY-100455R
    RK-33 (Standard)
    		Inhibitor
    RK-33 (Standard) is the analytical standard of RK-33 (HY-100455). This product is intended for research and analytical applications. RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33 (Standard)
  • HY-163738
    Furin-IN-2
    		Inhibitor
    Furin-IN-2 (compound P3) is a potent inhibitor of furin, with the IC50 of 35 μM. Furin-IN-2 shows antiviral activity.
    Furin-IN-2
  • HY-163713
    SARS-CoV-2-IN-89
    		Inhibitor
    SARS-CoV-2-IN-89 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells.
    SARS-CoV-2-IN-89
  • HY-180673
    Mpro/RdRp-IN-1
    		Inhibitor
    Mpro/RdRp-IN-1 (Compound 1) is a dual-target inhibitor against SARS-CoV-2, targeting RdRp (EC50 = 25.45) and Mpro (IC50 = 125.4 μM). Mpro/RdRp-IN-1 exhibits EC₅₀ for HCoV-OC43 of 4.79 μM, and the selectivity index (SI) is 10.89. Mpro/RdRp-IN-1 can be used for studying SARS-CoV-2 and HCoV-OC43 infections.
    Mpro/RdRp-IN-1
  • HY-182428
    UAWJ248
    		Inhibitor
    UAWJ248 is a SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection.
    UAWJ248
  • HY-178435
    SARS-CoV-2 Mpro-IN-48
    		Inhibitor
    SARS-CoV-2 Mpro-IN-48 is a potent SARS-CoV-2 main protease inhibitor with an IC50 of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19.
    SARS-CoV-2 Mpro-IN-48
  • HY-161777
    SARS-CoV-2 Mpro-IN-23
    		Inhibitor
    SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM.
    SARS-CoV-2 Mpro-IN-23
  • HY-171189
    C-467929
    		Inhibitor
    C-467929 is an Nsp15 endoribonuclease inhibitor with an IC50 of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research.
    C-467929
  • HY-177332
    SLC-391
    		Inhibitor
    SLC-391 is an orally active AXL kinase inhibitor with an IC50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer.
    SLC-391
  • HY-157539
    PB49673382
    		Inhibitor
    PB49673382 is a SARS-CoV-2 inhibitor. PB49673382 inhibits virus replication and consequent cytopathic effects of the virus with an IC50 of 6.42 μM.
    PB49673382
  • HY-157305
    Jun11165
    		Inhibitor
    Jun11165 is a SARS-CoV-2 PLpro inhibitor (IC50 ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC50 value of ≤ 6 μM. Jun11165 can be used in the research of viral infections.
    Jun11165
  • HY-N0886R
    Aloin B (Standard)
    		Inhibitor
    Aloin B (Isobarbaloin) (Standard) is the analytical standard of Aloin B. This product is intended for research and analytical applications. Aloin B is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 16.08 μM (hydrolytic activity) and 17.51 μM (deubiquitinase activity). Aloin B is metabolized by rat intestinal flora into aloe-emodin-9-anthrone to exert laxative effects. Aloin B inhibits TPA (HY-18739)-induced ear edema, putrescine elevation, and tumor promotion in mouse skin. Aloin B can be used in research related to anti-inflammation, tumor promotion inhibition, coronavirus disease 2019 (COVID-19) and constipation.
    Aloin B (Standard)
  • HY-111074
    DB12055
    		Inhibitor
    DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus.
    DB12055
  • HY-159932
    SARS-CoV-2 Mpro-IN-30
    		Inhibitor
    SARS-CoV-2 Mpro-IN-30 (compound L2) is a SARS-CoV-2 Mpro with the IC50 of 9.1 nM.
    SARS-CoV-2 Mpro-IN-30
  • HY-181192
    PROTAC SARS-CoV-2 Mpro degrader-6
    		Degrader
    PROTAC SARS-CoV-2 Mpro degrader-6 is a PROTACs degrader targeting the SARS-CoV-2 main protease (Mpro). PROTAC SARS-CoV-2 Mpro degrader-6 effectively induces the degradation of Mpro and increases K48-linked polyubiquitination of Mpro in HEK293 cells. PROTAC SARS-CoV-2 Mpro degrader-6 can be used in studies related to coronavirus disease 2019 (COVID-19).
    PROTAC SARS-CoV-2 Mpro degrader-6
Cat. No. Product Name / Synonyms Species Source